Download PDF
CC BY 4.0 · TH Open 2021; 05(02): e134-e138
DOI: 10.1055/s-0041-1727121
Case Report

Treatment of a Critically Ill COVID-19 Patient with the Seraph 100 Microbind Affinity Filter

Anke Pape
1   Kuratorium für Dialyse und Nierentransplantation, Pelikanplatz, Hannover, Germany
2   Department of Nephrology, Angiology and Rheumatology, KRH Klinikum Siloah, Hannover, Germany
3   Department of Nephrology, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany
,
Jan T. Kielstein 
4   Medical Clinic V Nephrology, Rheumatology, Blood Purification, Academic Teaching Hospital Braunschweig, Braunschweig, Germany
,
Tillman Krüger
1   Kuratorium für Dialyse und Nierentransplantation, Pelikanplatz, Hannover, Germany
2   Department of Nephrology, Angiology and Rheumatology, KRH Klinikum Siloah, Hannover, Germany
,
Thomas Fühner
5   Department of Respiratory and Critical Care Medicine, KRH Klinikum Siloah, Hannover, Germany
,
Reinhard Brunkhorst
1   Kuratorium für Dialyse und Nierentransplantation, Pelikanplatz, Hannover, Germany
2   Department of Nephrology, Angiology and Rheumatology, KRH Klinikum Siloah, Hannover, Germany
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has a serious impact on health and economics worldwide. Even though the majority of patients present with moderate and mild symptoms, yet a considerable portion of patients need to be treated in the intensive care unit. Aside from dexamethasone, there is no established pharmacological therapy. Moreover, some of the currently tested drugs are contraindicated for special patient populations like remdesivir for patients with severely impaired renal function. On this background, several extracorporeal treatments are currently explored concerning their potential to improve the clinical course and outcome of critically ill patients with COVID-19. Here, we report the use of the Seraph 100 Microbind Affinity filter, which is licensed in the European Union for the removal of pathogens. Authorization for emergency use in patients with COVID-19 admitted to the intensive care unit with confirmed or imminent respiratory failure was granted by the U.S. Food and Drug Administration on April 17, 2020.

A 53-year-old Caucasian male with a severe COVID-19 infection was treated with a Seraph Microbind Affinity filter hemoperfusion after clinical deterioration and commencement of mechanical ventilation. The 70-minute treatment at a blood flow of 200 mL/minute was well tolerated, and the patient was hemodynamically stable. The hemoperfusion reduced D-dimers dramatically.

This case report suggests that the use of Seraph 100 Microbind Affinity filter hemoperfusion might have positive effects on the clinical course of critically ill patients with COVID-19. However, future prospective collection of data ideally in randomized trials will have to confirm whether the use of Seraph 100 Microbind Affinity filter hemoperfusion is an option of the treatment for COVID-19.

Keywords

SARS-CoV-2 - extracorporeal treatment - circuit failure - D-dimer


Publication History

Received: 20 September 2020

Accepted: 21 January 2021

Article published online:
14 April 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Horby P, Lim WS, Emberson JR. et al; RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19 - preliminary report. N Engl J Med 2020; DOI: 10.1056/NEJMoa2021436.
    CrossrefPubMedGoogle Scholar
  • 2 Ronco C, Reis T. Kidney involvement in COVID-19 and rationale for extracorporeal therapies. Nat Rev Nephrol 2020; 16 (06) 308-310
    CrossrefPubMedGoogle Scholar
  • 3 Seffer MT, Eden G, Engelmann S, Kielstein JT. Elimination of Staphylococcus aureus from the bloodstream using a novel biomimetic sorbent haemoperfusion device. BMJ Case Rep 2020; 13 (08) 13
    CrossrefPubMedGoogle Scholar
  • 4 Seffer MT, Cottam D, Forni LG, Kielstein JT. Heparin 2.0: a new approach to the infection crisis. Blood Purif 2020; 1-7
    PubMedGoogle Scholar
  • 5 Bermejo-Martin JF, González-Rivera M, Almansa R. et al. Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19. Crit Care 2020; 24 (01) 691
    CrossrefPubMedGoogle Scholar
  • 6 Kim SY, Jin W, Sood A. et al. Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions. Antiviral Res 2020; 181: 104873
    CrossrefPubMedGoogle Scholar
  • 7 Malchesky PS. Therapeutic apheresis: why?. Ther Apher Dial 2015; 19 (05) 417-426
    CrossrefPubMedGoogle Scholar
  • 8 Olson SW, Oliver JD, Collen J. et al. Treatment for severe coronavirus disease 2019 with the seraph-100 microbind affinity blood filter. Crit Care Explor 2020; 2 (08) e0180
    CrossrefPubMedGoogle Scholar
  • 9 Zhang Q, Chen CZ, Swaroop M. et al. Targeting heparan sulfate proteoglycan-assisted endocytosis as a COVID-19 therapeutic option. bioRxiv 2020; DOI: 10.1101/2020.07.14.202549.
    CrossrefPubMedGoogle Scholar
  • 10 Young BE, Ong SWX, Kalimuddin S. et al; Singapore 2019 Novel Coronavirus Outbreak Research Team. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA 2020; 323 (15) 1488-1494
    CrossrefPubMedGoogle Scholar
  • 11 Chen W, Lan Y, Yuan X. et al. Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity. Emerg Microbes Infect 2020; 9 (01) 469-473
    CrossrefPubMedGoogle Scholar
  • 12 Hagman K, Hedenstierna M, Gille-Johnson P. et al. SARS-CoV-2 RNA in serum as predictor of severe outcome in COVID-19: a retrospective cohort study. Clin Infect Dis 2020; DOI: 10.1093/cid/ciaa1285.
    CrossrefPubMedGoogle Scholar
  • 13 Liu Y, Yan LM, Wan L. et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis 2020; 20 (06) 656-657
    CrossrefPubMedGoogle Scholar
  • 14 Zaid Y, Puhm F, Allaeys I. et al. Platelets can associate with SARS-Cov-2 RNA and are hyperactivated in COVID-19. Circ Res 2020; DOI: 10.1161/CIRCRESAHA.120.317703.
    CrossrefPubMedGoogle Scholar
  • 15 Bikdeli B, Madhavan MV, Gupta A. et al; Global COVID-19 Thrombosis Collaborative Group. Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research. Thromb Haemost 2020; 120 (07) 1004-1024
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Axelsson J, Ferreira M, Adolfsson L, McCrea K, Ward R, Larm O. Cytokines in blood from septic patients interact with surface-immobilized heparin. ASAIO J 2010; 56 (01) 48-51
    CrossrefPubMedGoogle Scholar
  • 17 Schmidt JJ, Eden G, Seffer MT, Winkler M, Kielstein JT. In-vitro elimination of anti-infective drugs by the Seraph 100 Microbind Affinity Blood Filter. Clin Kidney J sfaa063 2020; DOI: 10.1093/ckj/sfaa063.
    CrossrefPubMedGoogle Scholar
  • 18 Seffer MT, Martens-Lobenhoffer J, Schmidt JJ, Eden G, Bode-Böger SM, Kielstein JT. Clearance of chloroquine and hydroxychloroquine by the Seraph 100 Microbinda Affinity Blood Filter -a device approved for the treatment of COVID-19 patients. Ther Apher Dial 2020; DOI: 10.1111/1744-9987.13549.
    CrossrefPubMedGoogle Scholar
  • 19 Han H, Yang L, Liu R. et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med 2020; 58 (07) 1116-1120
    CrossrefPubMedGoogle Scholar
  • 20 Chen G, Wu D, Guo W. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020; 130 (05) 2620-2629
    CrossrefPubMedGoogle Scholar
  • 21 Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020; 18 (05) 1094-1099
    CrossrefPubMedGoogle Scholar
  • 22 Weber M, Mitrovic V, Hamm C. B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide - Diagnostic role in stable coronary artery disease. Exp Clin Cardiol 2006; 11 (02) 99-101
    PubMedGoogle Scholar